Claris Biotherapeutics has secured $118 million in funding to advance its experimental eye drug, CSB-001, targeting limbal stem cell deficiency (LSCD). The New Jersey-based biotech has also appointed new leadership to bolster its efforts in this therapeutic area.
The Series B funding round was co-led by Samsara BioCapital and Catalio Capital Management, alongside other investors such as Sofinnova Investments and Novo Holdings. Claris aims to initiate late-stage testing for CSB-001 early next year, addressing a condition that can severely impair vision due to the depletion of limbal stem cells in the eye. Currently, LSCD affects an estimated 30,000 people in the U.S., with many more likely undiagnosed due to overlapping symptoms with other eye disorders.
Stephen Brady, the new CEO of Claris, emphasized the growing recognition of opportunities within ophthalmology, stating that the company is committed to developing CSB-001, which targets hepatocyte growth factor to aid in tissue repair. The drug was initially licensed from Kringle Pharma and has shifted focus from neurotrophic keratitis to LSCD based on promising preliminary data.
With plans for larger studies and potential public market entry, Claris is also enhancing its executive team, appointing Marc de Garidel as board chair and Brian Baum as chief commercial officer. Both bring extensive experience, particularly in launching innovative therapies for eye conditions, positioning Claris to make significant strides in the ophthalmic space.